Itacitinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Itacitinib
Accession Number
DB12154
Type
Small Molecule
Groups
Investigational
Description

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
INCB-039110 / INCB039110
Categories
UNII
19J3781LPM
CAS number
1334298-90-6
Weight
Average: 553.526
Monoisotopic: 553.196169049
Chemical Formula
C26H23F4N9O
InChI Key
KTBSXLIQKWEBRB-UHFFFAOYSA-N
InChI
InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
IUPAC Name
2-(1-{1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl}-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
SMILES
FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
53380437
PubChem Substance
347828448
ChemSpider
35033258
BindingDB
246868
ChEMBL
CHEMBL3622820

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Tumors, Solid1
1Active Not RecruitingTreatmentB-Cell Malignancies1
1CompletedTreatmentGraft Versus Host Disease, Acute / Graft-versus-host Disease (GVHD)1
1Not Yet RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Hodgkins Disease (HD) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
1Not Yet RecruitingTreatmentMetastatic Leiomyosarcoma / Metastatic Synovial Sarcoma / Metastatic Undifferentiated Pleomorphic Sarcoma / Round Cell Liposarcoma1
1RecruitingPreventionMalignancies, Hematologic1
1RecruitingTreatmentAcute Graft-Versus-Host Disease1
1RecruitingTreatmentAdvanced Solid Tumors / Cancer, Breast / Colorectal Cancer (CRC) / CRC (Colorectal Cancer) / Endometrial Cancers / Head and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma / Microsatellite Unstable (MSI) Colorectal Cancer / MMR-deficient Tumors / Pancreatic Ductal Adenocarcinoma / RCC (Renal Cell Carinoma) / Renal Cell Adenocarcinoma / SCCHN (Head and Neck Squamous Cell Carcinoma) / Transitional Cell Carcinoma of the Genitourinary Tract / Triple Negative Breast Cancer (TNBC) / Tumors, Solid / UC (Urothelial Cancer)1
1RecruitingTreatmentMelanoma1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced / Metastatic Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentB-Cell Malignancies1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas / Metastatic Cancers / Pancreatic Cancer Metastatic / Tumors, Solid1
1, 2Not Yet RecruitingTreatmentAcute Graft-Versus-Host Disease1
1, 2Not Yet RecruitingTreatmentBronchiolitis Obliterans Syndrome (BOS)1
1, 2RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / NSCLC (Non-small Cell Lung Carcinoma)1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / NHL - Non-Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentMPN (Myeloproliferative Neoplasms) / Post Essential Thrombocythemia Myelofibrosis / Post Polycythemia Vera Fibrosis / Primary Myelofibrosis1
2CompletedTreatmentChronic Plaque Psoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
2CompletedTreatmentRheumatoid Arthritis1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / MPN (Myeloproliferative Neoplasms)1
2RecruitingTreatmentGraft Versus Host Disease (GVHD) / Low Risk Acute Graft-versus-host Disease1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentModerate to Severe Ulcerative Colitis1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / NSCLC (Non-small Cell Lung Carcinoma)1
2TerminatedTreatmentRecurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma1
2WithdrawnTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC) / NSCLC (Non-small Cell Lung Carcinoma) / Solid Tumors and Hematologic Malignancy1
2WithdrawnTreatmentPruritis1
3Active Not RecruitingTreatmentAcute Graft-Versus-Host Disease / Graft-versus-host Disease (GVHD)1
3RecruitingTreatmentChronic Graft Versus Host Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0232 mg/mLALOGPS
logP2.35ALOGPS
logP1.88ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)6.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area119.62 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity146.86 m3·mol-1ChemAxon
Polarizability51.98 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids and derivatives
Alternative Parents
Pyrrolo[2,3-d]pyrimidines / N-acylpiperidines / Aminopiperidines / Pyrimidines and pyrimidine derivatives / Aryl fluorides / Vinylogous halides / Tertiary carboxylic acid amides / Pyrroles / Pyrazoles / Heteroaromatic compounds
show 10 more
Substituents
Pyrrolo[2,3-d]pyrimidine / N-acyl-piperidine / Pyridine carboxylic acid or derivatives / Pyrrolopyrimidine / 4-aminopiperidine / Aryl fluoride / Aryl halide / Piperidine / Pyrimidine / Azole
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:29 / Updated on June 04, 2019 07:32